*To be consumed as directed by physician.
Therapies:
Supportive
Composition:
Sorafenib Tosylate 200 mg
Orib 200Mg Tablet belongs to the anti-cancer group of medicines. It consists of the active ingredient Sorafenib, which is indicated for advanced renal cell carcinoma (kidney cancer), advanced hepatocellular carcinoma (liver cancer) in patients ineligible for surgery, and differentiated thyroid carcinoma (thyroid cancer) in patients who are not responsive to radioactive iodine therapy.
Diarrhea, tiredness, stomach pain, nausea, weakness, rashes, flu-like illness, appetite loss, nausea, weight loss, and low blood calcium levels are common side effects of orib 200mg Tablet. Inform your doctor if any of these side effects disturb or persist with you.
Inform your doctor if you are allergic to this Tablet and its ingredients. Before starting treatment with this tablet, you should tell your physician if you have heart problems, chest pain, bleeding problems, high blood pressure, or have had or are about to have surgery. Use effective contraception during the therapy and for 6 months after the last dose if you are a woman or 3 months after the last dose if you are a man.
*To be consumed as directed by physician.
